Unlocking precision medicine: An overview of Illumina’s TSO500

Life Sciences, Drug Discovery & Development, Biomarkers, Laboratory Technology, Fundamental Research,
  • Monday, June 17, 2024 | 10am EDT (NA) / 3pm BST (UK) / 4pm CEST (EU-Central)
  • 60 min

ICON’s experience with the TSO500 solid and liquid biopsy assay

As next-generation sequencing (NGS) becomes a ubiquitous part of routine cancer care, its impact in designing and refining drug development remains in flux. Clinical trial design, biomarker identification and cohort analysis have begun to adapt to the changing landscape over the past decade; however, there are challenges with standardization and federation of data.

In this webinar, the speakers will explore the only kitted comprehensive genomic profiling (CGP) assay submitted to the US Food and Drug Administration (FDA) for pre-market approval (PMA) up to this point, TruSight Oncology 500 (TSO500). Available as a research-use-only tool, TSO500 sets the standard for reproducibility across sites, with exceptional accuracy and specificity across a broad range of preserved tissue types.

The expert speakers will also provide an overview of CGP and cover the validation of TSO500 tissue and present preliminary data on circulating tumor DNA (ctDNA). Moreover, the session will explore the application of NGS in oncology clinical trial biomarker studies, demonstrating its pivotal role in advancing personalized medicine in cancer treatment.

Register for this webinar today to gain insights on using NGS in biomarker studies and the impact of comprehensive genomic profiling on advancing personalized cancer treatment.


Jin Li, ICON

Jin Li, Senior Director, Scientific Affairs, ICON

Jin Li has been in the molecular diagnostics and oncology biomarker field for over 20 years. His current role at ICON includes leading ICON’s NGS specialty lab on assay development and clinical trial assay testing. Prior to working at ICON, he spent seven years at MolecularMD building and leading NGS testing in oncology biomarker testing in clinical trials (MolecularMD was acquired by ICON in 2019).


Before MolecularMD, he spent two years at Genzyme Genetics, developing high-complexity genetic tests. Jin’s academic credentials include an MD from Tianjin Medical University and a PhD in Molecular and Cellular Physiology from Tufts University.

After completing his doctorate, he served as a postdoctoral researcher and instructor at the Dana-Farber Cancer Institute at Harvard Medical School, where he made critical contributions to the inventions of a novel real-time PCR method and a mutation enrichment method, COLD-PCR.

Read Less...

Message Presenter
Jason Gottwals, Illumina

Jason Gottwals, Genomic Enablement Manager - AMR, Illumina

Jason Gottwals has been in the molecular diagnostics field for over 22 years. His current role at Illumina is designed to help large cancer sequencing operations recognize and execute opportunities for success. Prior to Illumina, he spent 10 years at PathGroup (PG) designing and executing an oncology program in partnership with Dr. Pranil Chandra, now Chief Genomics Officer at PG.

Message Presenter

Who Should Attend?

This webinar will appeal to senior professionals/scientists from biotech and large pharma companies involved in:

  • Biomarker/Clinical biomarker development
  • Biomarker and diagnostics
  • Genomics
  • Immuno-oncology
  • Medicinal chemistry
  • Translational medicine

What You Will Learn

Attendees will learn about:

  • An overview of comprehensive genomic profiling (CGP)
  • Accuracy and variability of distributed kit: TSO500 RUO
  • Validation of TSO500 tissue and preliminary data on circulating tumor DNA (ctDNA)
  • The application of next-generation sequencing in oncology clinical trial biomarker studies

Xtalks Partner


ICON is the world’s leading clinical research organisation, powered by healthcare intelligence. From molecule to medicine, we advance clinical research by providing a comprehensive suite of outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. Our outsourcing models can be adapted to suit small local trials to large global programs, including full service, standalone services, FSP and full asset development.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account